Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Higher HERV-W and IFN-I Antibody Presence Detected in Intensive Care COVID-19 Patients | LifeTein Peptide Blog

As the world moves on through the ongoing pandemic that is COVID-19, great minds across every field and corner of the world are doing their part to further our collective understanding of the virus. A recent study specifically took greater notice in the popula

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

As the world moves on through the ongoing pandemic that is COVID-19, great minds across every field and corner of the world are doing their part to further our collective understanding of the virus. A recent study specifically took greater notice in the population of antibodies increasing in more sever cases of COVID-19 over mild ones. Specifically, there was a study conducted on the higher HERV-W and IFN-I antibody presence detected in intensive care COVID-19 patients, utilizing peptides for the experiment. HERV-W and IFN-I antibody presence higher in severe COVID-19 casesLifeTein supplied the group with the HERV-W-env(248–262), IFN-α, and IFN-ω peptides necessary for the report. Not only did the studies prove higher levels of anti-IFN-I autoantibodies and HERV-W antibodies are much more prevalent in severe COVID-19 cases than in mild ones, but it opened up a new perspective on how the humoral responses against HERV-W-env(248–262) and IFN-α are correlated across ICU patients. Hopefully, this research leads to more beneficial breakthroughs over time, for COVID-19 cases and potentially other life-threatening conditions as well.Simula, E. R., Manca, M. A., Noli, M., Jasemi, S., Ruberto, S., Uzzau, S., Rubino, S., Manca, P., & Sechi, L. A. (2022). Increased Presence of Antibodies against Type I Interferons and Human Endogenous Retrovirus W in Intensive Care Unit COVID-19 Patients. In H. H. Mostafa (Ed.), Microbiology Spectrum. American Society for Microbiology. https://doi.org/10.1128/spectrum.01280-22

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

Clinical Trials and Research

Several clinical trials have explored the use of PADRE in cancer vaccines. For instance, vaccines targeting Mucin 1 (MUC1), a glycoprotein overexpressed in many cancers, have shown promising results when combined with PADRE. These vaccines have demonstrated the ability to elicit strong immune responses, including the production of antibodies against cancer-specific antigens.

Source: lifetein.com ↗

Studying Cell-Cell Interactions with LIPSTIC

In immunology research, Cy7-labelled LPETGG peptides have proven instrumental in the LIPSTIC (Labelling Immune Partnerships by SorTagging Intercellular Contacts) technique. This elegant method uses bacterial sortase A to enzymatically transfer fluorescent dyes from the LPETGG substrate onto interacting cell surfaces, enabling researchers to track dynamic immune partnerships in vivo and in vitro with single-cell resolution. Such applications underscore the versatility of Cy7 beyond simple structural labelling.

Source: lifetein.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How to solubilize my synthetic peptides? #

Please refer to this FAQ for details: Handling and Storage of Synthetic Peptides. If the peptides are still cloudy, or turbid, you may have reached the limit of solubility. When the peptides are insoluble in the buffer, please try to sonicate, centrifuge, and lyophilize the peptide. Make sure to break the lyophilized lumps into a fine powder. Then try a small volume of a good agent 8M Urea, NMP, DMF, or DMSO to dissolve the peptide. Then dilute with water or your desired buffer. For peptides with Arg or LYs, you should try to lower the pH to 6 because the protonated amino acids will help solubility. Sonication and the following solvents may help with difficult peptides: 1) Begin with 100 % acetonitrile then dilute with water until 50% 2) Begin with 100% DMSO then dilute with water until 30 % 3) Dissolve it with 8M Urea 4) Dissolve it with 6 or 8 M Guanidine hydrochloride 5) 6M GuHCL, 0.05% TFA, pH2, 6) 100% TFA 7) 40% AcOH, 30%ACN, 30% water

Source: lifetein.com ↗
Storage reference

Chemical Stability

Cy3 is chemically stable and can be conjugated to various biomolecules without significant loss of fluorescence. This stability is essential for long-term imaging and tracking experiments.

Source: lifetein.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides